Bansal S, Burman A, Tripathi AK. Advanced glycation end products: Key mediator and therapeutic target of cardiovascular complications in diabetes. World J Diabetes 2023; 14(8): 1146-1162 [PMID: 37664478 DOI: 10.4239/wjd.v14.i8.1146]
Corresponding Author of This Article
Savita Bansal, PhD, Assistant Professor, Department of Biochemistry, Institute of Home Sciences, University of Delhi, Hauz Khas, New Delhi 110016, India. savita.bansal@ihe.du.ac.in
Research Domain of This Article
Biochemistry & Molecular Biology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Savita Bansal, Department of Biochemistry, Institute of Home Sciences, University of Delhi, New Delhi 110016, India
Archana Burman, Department of Biochemistry, Institute of Home Economics, University of Delhi, New Delhi 110016, India
Asok Kumar Tripathi, Department of Biochemistry, University College of Medical Sciences, University of Delhi, New Delhi 110095, India
Author contributions: Bansal S frames the review article; all authors have read and approved the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Savita Bansal, PhD, Assistant Professor, Department of Biochemistry, Institute of Home Sciences, University of Delhi, Hauz Khas, New Delhi 110016, India. savita.bansal@ihe.du.ac.in
Received: January 29, 2023 Peer-review started: January 29, 2023 First decision: March 1, 2023 Revised: March 21, 2023 Accepted: May 22, 2023 Article in press: May 22, 2023 Published online: August 15, 2023
Core Tip
Core tip: Cardiovascular diseases (CVDs) in type 2 diabetes mellitus impose a clinical and an economic burden on the healthcare system. Early diagnosis of diabetes may prevent its progression to complications and decrease its associated comorbidities. The present manuscript reports the clinical relevance of estimating advanced glycation end products (AGEs) in diabetes. The deleterious effects of AGEs include many important biochemical reactions central to the development and progression of cardiovascular complications in diabetes. Therefore, AGEs are one of the important targets for future diagnosis and prevention of diabetes. The epidemiology of CVD in diabetes, AGEs as a crucial mediator of diabetic CVD, and an overview of different strategies for countering the accumulation of AGEs is discussed along with new therapeutic interventions to ameliorate their effects.
